Amoxicillin (Otitis Media / Sinusitis)
Brand names: Amoxil
Amoxicillin is a broad-spectrum penicillin used for respiratory, ENT, urinary and other infections, and within Helicobacter pylori eradication.
Adult dose
Paediatric dose
Dose adjustments
Adults and children ≥ 40 kg: GFR greater than 30 mL/min — no adjustment necessary; GFR 10 to 30 mL/min — maximum 500 mg twice daily; GFR less than 10 mL/min — maximum 500 mg/day. Haemodialysis (adults and children over 40 kg): 500 mg every 24 h, with one additional 500 mg dose before dialysis and a further 500 mg after dialysis to restore circulating drug levels. Peritoneal dialysis: maximum 500 mg/day. In children < 40 kg parenteral therapy is preferred in the majority of cases (see paedDose notes for the paediatric renal figures).
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKAdults and Pediatric Patients greater than 40 kg: 500 or 875 mg every 12 hours or 250 or 500 mg every 8 hours, based on the amoxicillin component. ( 2.2 , 2.3 ) Pediatric patients aged 12 weeks (3 months) and older: 25 to 45 mg/kg/day every 12 hours or 20 to 40 mg/kg/day every 8 hours, up to the adult dose. ( 2.3 ) Neonates and infants less than 12 weeks of age: 30 mg/kg/day divided every 12 hours, based on the amoxicillin component. Use of the 125 mg/5 mL oral suspension is recommended. ( 2.3 ) 2.1 Important Administration Instructions Amoxicillin and Clavulanate Potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when Amoxicillin and …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-04-30. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Contraindications
- Hypersensitivity to the active substance, to any of the penicillins or to any of the excipients
- History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam)
Side effects
- Common: diarrhoea and nausea (clinical trial data)
- Common: skin rash; uncommon urticaria and pruritus
- Uncommon: vomiting
- Very rare: severe allergic reactions including angioneurotic oedema, anaphylaxis, serum sickness and hypersensitivity vasculitis; not known — Kounis syndrome
- Very rare: antibiotic-associated colitis (including pseudomembranous and haemorrhagic colitis); hepatitis and cholestatic jaundice; interstitial nephritis and crystalluria (including acute renal injury)
- Very rare: severe cutaneous reactions — erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis, AGEP and DRESS; reversible leucopenia, thrombocytopenia and haemolytic anaemia; convulsions
Clinical monograph
How it works
A beta-lactam that inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins.
Prescribing in practice
- Contraindicated in penicillin allergy; it commonly causes a non-allergic rash in glandular fever, so avoid it empirically there.
- Many respiratory/ENT infections are viral or self-limiting — prescribe per local guidance and consider delayed prescribing.
- Reduce the dose in significant renal impairment.
Monitoring
Short courses need no routine monitoring; review response and adverse effects.
Counselling the patient
- Complete the prescribed course.
- Report a rash, swelling or difficulty breathing (possible allergy).
- Report severe or prolonged diarrhoea.
Evidence & guidelines
First-line for many bacterial respiratory/ENT infections per NICE/PHE antimicrobial guidance, within antibiotic-stewardship principles.
Reference: NICE NG98 AOM; PHE AOM Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- C-Peptide to Glucose Ratio · Diabetes Classification
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Lund-Mackay CT Score for Chronic Rhinosinusitis · Sinonasal
- Acute Rhinosinusitis Severity (EPOS Criteria) · Rhinosinusitis
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020